Up-regulating PPAR-γ expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: The possible antiatherogenic and antithrombotic effects of atorvastatin

International Journal of Cardiology

Volumn 139, Issue 3, 2010, Pages 213-217

  Yang, Ping ^a   Li, Ying ^a   Li, Jian Jun ^b   Qin, Ling ^c   Li, Xue Yu ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Atherosclerosis; Atorvastatin; Lipid; NO; PAI 1; PPAR gamma

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; FIBRINOLYTIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIATHEROGENIC ACTIVITY; ANTITHROMBOTIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG ACTIVITY; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; UPREGULATION; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FIBRINOLYTIC AGENTS; HEPTANOIC ACIDS; MALE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; PYRROLES; RABBITS; UP-REGULATION;

EID: 80052526279     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.10.019     Document Type: Article

References (26)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
2. Panunti B, Fonseca V. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vasc Pharmacol 2006;45:29-35.
3. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferatoractivated receptor agonists. Diabetes 2005;54:2460-70.
4. Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur J Pharmacol 2004;483:79-93.
5. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. New Engl J Med 2000;342:1792-801.
6. Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPAR-γ alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-6.
7. Pasceri V, Wu HD, Willerson JT, Yeh ETH. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000;101:235-8.
8. Marx N, Walcher D. Vascular effects of PPARγ activators - from bench to bedside. Prog Lipid Res 2007;46:283-96.
9. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:52-7.
10. Ptasinska A, Wang S, Zhang J, Wesley RA, Danner RL. Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway. Faseb J 2007;21:950-61.
11. Kato K, Satoh H, Endo Y, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPAR gamma in endothelial function. Biochem Biophys Res Commun 1999;258:431-5.
12. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006;109:7-15.
13. Liao JK. Statins: potent vascular anti-inflammatory agents. Int J Clin Pract Suppl 2004;143:41-8.
14. Rajamannan NM, Subramaniam M, Stock SR, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005;91:908-10.
15. Li JQ, Zhao SP, Li QZ, et al. Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits. Clin Chim Acta 2006;370:57-62.
16. Zhao SP, Zhang DQ. Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 2003;336:103-8.
17. Scandinavian Simvastatin Survival Study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
18. Shepherd J, Cobbe SM, Ford I, Isles CG. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301-7.
19. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acutecoronary events with lovastatin in men and women with averagecholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
20. Schild RL, Schaiff WT, Carlson MG, Cronbach EG, Nelson DM, Sadovsky Y. The activity of PPAR gamma in primary human trophoblasts is enhanced by oxidized lipids. J Clin Endocrinol Metab 2002;87:1105-10.
21. Song CY, Kim BC, Hong HK, Lee HS. Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF-beta signaling in mesangial cells. Kidney Int 2005;67:1743-52.
22. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336-46.
23. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999;103:897-905.
24. Maas R, Schwedhelm E, Kahl L, et al. Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxidemediated signaling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem 2008;54:292-300.
25. Puddu P, Puddu GM, Muscari A. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? Int J Cardiol 2003;90:133-40.
26. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131: 149-50.